Outcome of M-IGHV CLL patients according to the mutational status of MYD88. Actuarial curves for (A) time to first treatment in Binet stages A and B and (B) overall survival of mutant (solid line) and wild-type (dashed line) MYD88 CLL patients with mutated IGHV.